Nebulisable liposomes – Method for the pulmonary delivery of agents
The treatment of lung and respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD), pneumonia and pulmonary hypertension, is carried out by means of agents with a long biological half-life. Liposomes are favoured that remain as stable as possible during nebulisation and that achieve a delayed release of the agent with as few side-effects as possible.
The liposome formulations at hand fulfil these requirements of the delivery of pharmaceutical agents to the lung in an outstanding manner. They are characterised by a good tolerance, because they are composed out of the body's own substances that are found naturally in the lung. The composition of liposomes is selected in such a way that the agents packed therein are released selectively and over a specific period of time, in a controlled manner.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…
